Cyproheptadine and Chlorpromazine Effects on Spasticity
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The main goal of this research is to understand the neuronal mechanisms that mediate the development of spasticity and motor dysfunction after spinal cord injury. The investigators examine how neurons and neuronal circuits in an injured nervous system adapt to produce the uncontrolled and unwanted muscle contractions that affect the majority (80%) of patients with spinal cord injury. One of the neurons that the investigators study is the motoneuron that excites the muscles of the limbs to produce movement. Previously, the investigators have shown that after spinal cord injury, the excessive and uncontrolled activity of motoneurons during muscle spasms is mediated, in large part, by the activation of calcium currents in the human motoneuron. In human patients the investigators have used recordings from single muscle fibres to estimate the contribution of these calcium currents in activating the motoneuron during muscle spasms. In this proposal, the investigators study why motoneurons recover these calcium currents and self-sustained activity after chronic spinal cord injury. Because the calcium currents require the presence of the monoamine serotonin (5HT) to activate, and this monoamine is greatly reduced after injury, the investigators examine if the calcium currents recover because the 5HT receptors become spontaneously active without the need for 5HT to bind to the receptor, which the investigators hypothesize to be one of the causes of spasticity after spinal cord injury. This research will pave the way to develop new pharmacological and rehabilitative therapies to both control spasticity after spinal cord injury and augment residual motor movements.
| Condition |
|---|
|
Spinal Cord Injuries Muscle Spasticity |
| Study Type: | Observational |
| Official Title: | Phase 3 Study of Cyproheptadine and Chlorpromazine Effects on Spasticity After Spinal Cord Injury |
- Cutaneomuscular Reflex Responses [ Time Frame: Change after drug intake at baseline, 30minutes, 60minutes, 90minutes and 120minutes ] [ Designated as safety issue: No ]Tibialis anterior reflex responses evoked by stimulation of the medial arch of the foot will be measured before and after drug administration.
- Paired motor unit recordings [ Time Frame: Change at baseline and 30, 60, 90 and 120min after drug intake ] [ Designated as safety issue: No ]We obtain paired motor unit recordings to determine changes in neuronal excitability after drug intake in incomplete spinal-cord injured subjects only.
- Blood pressure and Heart rate [ Time Frame: Change at baseline and 30, 60, 90, 120 minutes after drug intake ] [ Designated as safety issue: Yes ]We measure blood pressure and heart rate to determine the safety of the drug during the experiment and whether we can continue safely.
| Enrollment: | 20 |
| Study Start Date: | July 2010 |
| Study Completion Date: | November 2012 |
| Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Complete Spinal Cord Injured Subjects
Patients with no motor scores in their legs and suffering a complete spinal cord injury.
|
|
Incomplete Spinal Cord Injured Subjects
Patient with some motor preservation below the injury and suffering an incomplete spinal cord injury.
|
Eligibility| Ages Eligible for Study: | 17 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Spinal Cord Injury Patients
Inclusion Criteria:
Patients must have suffered a trauma to the spinal cord at least 6 months ago or longer. In addition, subjects must exhibit some degree of spasticity as determined by having an Ashworth Spasticity Score, as assessed by a physical therapist, greater than 1.
Exclusion Criteria:
- If patients have damage to the nervous system other than to the spinal cord
- Pregnant women
- Elderly Patients and debilitated patients
- Alcoholic Patients
Patients with:
- Known or suspected allergy to the medication or its ingredients
- Cardiovascular disease
- Hypotension
- Coronary artery disease
- Reduced liver or kidney function
- Comatose or depressed states due to CNS depressants
- Blood dyscrasias
- Bone marrow depression
- History of seizures
- Respiratory problems
- Hypocalcemia
- Monoamine oxidase inhibitor therapy
- Angle-closure glaucoma
- Stenosing peptic ulcer
- Symptomatic prostatic hypertrophy
- Bladder neck obstruction
- Pyloroduodenal obstruction
- History of bronchial asthma
- Increased intraocular pressure
- Hyperthyroidism
- Cardiovascular disease
- Hypertension
Patients taking:
- Amphetamines
- Antihistamines-second generation
- Anticonvulsants
- Anticholinergics
- CNS depressants
- Antidepressants
- Hypotensive agents
- Levodopa
- Lithium
Contacts and Locations
More Information
Additional Information:
Publications:
| Responsible Party: | University of Alberta |
| ClinicalTrials.gov Identifier: | NCT01509885 History of Changes |
| Other Study ID Numbers: | Pro00020682 |
| Study First Received: | January 10, 2012 |
| Last Updated: | November 16, 2012 |
| Health Authority: | Canada: Health Canada Canada: Ethics Review Committee |
Additional relevant MeSH terms:
|
Muscle Spasticity Spinal Cord Injuries Muscular Diseases Musculoskeletal Diseases Muscle Hypertonia Neuromuscular Manifestations Neurologic Manifestations Nervous System Diseases Signs and Symptoms Spinal Cord Diseases Central Nervous System Diseases Trauma, Nervous System Wounds and Injuries Cyproheptadine Chlorpromazine |
Anti-Allergic Agents Therapeutic Uses Pharmacologic Actions Antipruritics Dermatologic Agents Gastrointestinal Agents Histamine H1 Antagonists Histamine Antagonists Histamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Serotonin Antagonists Serotonin Agents Antiemetics |
ClinicalTrials.gov processed this record on May 23, 2013